Survival of dental implants in post-menopausal bisphosphonate users

Journal of Prosthodontic Research

Volumn 54, Issue 3, 2010, Pages 108-111

  Koka, Sreenivas ^a   Babu, Nivedhitha Malli Suresh ^a   Norell, Aaron ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bisphosphonate; Dental implant; Osteonecrosis of the jaw

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; TOOTH IMPLANT;

BONE NECROSIS; CHEMICALLY INDUCED; FEMALE; HUMAN; JAW DISEASE; POSTMENOPAUSE; PROSTHESIS FAILURE; RETROSPECTIVE STUDY; TOOTH IMPLANT;

DENTAL IMPLANTS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; OSTEONECROSIS; POSTMENOPAUSE; PROSTHESIS FAILURE; RETROSPECTIVE STUDIES;

EID: 77955570810     PISSN: 18831958     EISSN: 22124632     Source Type: Journal    
DOI: 10.1016/j.jpor.2010.04.002     Document Type: Article

References (11)

1. Marx R.E., Sawatari Y., Fortin M., Brouman V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575.
2. Madrid C., Sanz M. What impact do systemically administered bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res 2009, 20(Suppl.):87-95.
3. Grant B.T., Amenedo C., Freeman K., Kraut R.A. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008, 66:223-230.
4. Bell B.M., Bell R.E. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 2008, 66:1022-1024.
5. Beebe T.J., McRae J.A., Harrison P.A., Davern M.E., Quinlan K.B. Mail surveys resulted in more reports of substance abuse than telephone surveys. J Clin Epidemiol 2005, 58:421-424.
6. Erhart M., Wetzel R.M., Krugel A., Ravens-Sieberer U. Effects of phone versus mail survey methods on the measurement of health-related quality of life and emotional and behavioural problems in adolescents. BMC Public Health 2009, 9:491.
7. Oizumi T, Funayama H, Yamaguchi K, Yokoyama M, Takahashi H, Yamamoto M, et al. Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a Non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. J Oral Maxillofac Surg 2010 Feb 13, [Epub ahead of print], doi:10.1016/j.joms.2009.08.027.
8. Weycker D., Macarios D., Edelsberg J., Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 2006, 17:1645-1652.
9. Siris E.S., Harris S.T., Rosen C.J., Barr C.E., Arvesen J.N., Abbott T.A., et al. Mayo Clin Proc 2006, 81:1013-1022.
10. Weycker D., Macarios D., Edelsberg J., Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporosis Int 2007, 18:271-277.
11. Siris E.S., Shelby P.L., Saag K.G., Borgstron F., Herings R.M., Silverman S.L. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009, 122:3-13.